U.S. Federal
U.S. Federal
Beyond Reefer Madness: The U.S. Fed's role in cannabis policy.
The magnified focus on economic incentives and tax revenue has overshadowed the significance of cannabis as medicine.
Quick Hit
Doctors at the Mayo Clinic recently highlighted a case of price gouging on vitamin K1.
Quick Hit
How will botanical CBD be regulated when cannabidiol is approved as a pharmaceutical?
Article
In December of 2016, the DEA announced that it is implementing new rules that may portend a crackdown on CBD oil products. Educate yourself.
Article
Why are the FDA and DEA trying to block people's access to kratom by making it a Schedule 1 drug?
Article
Huge interest in the medicinal potential of CBD has catalyzed a rebirth of industrial hemp in the U.S. But is hemp the best source of CBD?
Article
Jahan Marcu discusses lab testing, safety protocols, adverse events reporting, and regulatory standards for the cannabis industry.
Video
Several Cannabis-related bills have been introduced by the U.S. Congress in the current 114th Session. Three of these relate specifically to CBD.
Article
Industrial hemp oil marketers tried to put a positive spin on the FDA’s recent slap-down of companies that pitch CBD products as legal in all 50 states.
Article
Top Stories
THE ESSENTIAL GUIDE TO CBD
By the Editors of Reader’s Digest & Project CBD: Everything You Need to Know About What It Helps, Where to Buy It, and How to Take It.